Lunai Bioworks (LNAI) Q4 2026 earnings summary

Executive summary

• FY26 remained pre-commercial: service revenue was $51,992 from one research-services customer; no product sales, and substantial doubt about continuing as a going concern persisted.

• The portfolio combines preclinical cell/gene therapy programs, BioSymetrics’ AI-enabled research platform, biodefense work and the acquired N2B intranasal delivery platform.

• FY26 net loss narrowed sharply versus FY25, primarily reflecting the absence of the prior-year goodwill impairment, lower G&A and a gain on GEDi Cube’s deconsolidation; cash runway remained critical after year-end.

Financial highlights

• FY26 revenue and gross profit were each $51,992; operating expenses were $8,749,925 and loss from operations was $8,697,933.

• FY26 net loss was $3,562,479 versus $178,007,489 in FY25; FY25 included $170.4M of goodwill impairment, while FY26 included a $12.0M bankruptcy gain and $7.4M debt-extinguishment loss.

• G&A fell 56% to $7,799,970 and R&D fell 95% to $24,518; operating expenses declined 95%, largely due to lower noncash goodwill impairment.

• Cash was $1,713,653 at June 30, 2026, versus $92,700 a year earlier; working capital deficit was $16,874,093 and total liabilities were $18,966,734.

Outlook and guidance

• Management expects no material product revenue until products receive marketing approval; FY27 funding, if obtained, is expected to cover obligations, working capital, development and commercialization needs.

• As of October 13, 2026, available cash covered less than one month under the current operating plan; financing is being pursued, with potential reductions, suspension or cessation of operations if funds are unavailable.

• If capital becomes available, intended investment includes AI-platform validation, therapeutic and biodefense programs, with related SG&A and R&D spending expected to rise.